<?xml version="1.0" encoding="utf-8"?>
<recommendedContent xmlns="http://api.mspoke.com">
    <recommendedItem id="20100101_19_449"
                     title="FDA Okays Statin for Primary Prevention"
                     score="0.014"
                     href="http://www.medpagetoday.com/InfectiousDisease/PublicHealth/tb/18380?impressionId=1265776941503"
                     
      &lt;p&gt;WASHINGTON  --  The FDA has approved rosuvastatin (Crestor) for primary prevention of cardiovascular disease, making it the first statin to receive this indication.&lt;/p&gt;
&lt;p&gt;The new labeling, recommended by an FDA advisory panel late last year, also marks the first time that a drug label will include an indication based on the biomarker highly-sensitive C-reactive protein, an inflammatory marker.&lt;/p&gt;
&lt;p&gt;The new indication would be for men 50 or older and women 60 or older who have fasting LDL of less than 130 mg/dL, a highly-sensitive CRP of 2.0 mg/L or greater, triglycerides of less than 500 mg/dL, and no prior history of heart attack or stroke, or coronary heart disease risk.&lt;/p&gt;
&lt;p&gt;The basis for the new labeling was the JUPITER trial, a randomized, placebo-controlled trial of 17,802 men and women with a mean age of 66 and no history of atherosclerosis. All participants had LDL of less than 130 mg/dL and a highly-sensitive C-reactive protein concentration of 2 mg/L or higher.&lt;/p&gt;
&lt;p&gt;Patients were randomized to 20 mg of rosuvastatin for 1.9 years, which reduced median LDL cholesterol to 55 mg/dL, down from a median of 108 mg/dL at baseline. The corresponding relative reduction in the rate of MI, stroke, arterial revascularization, or cardiovascular death was 44% (&lt;em&gt;P&lt;/em&gt;&amp;lt;0.00001).&lt;/p&gt;
&lt;p&gt;The number needed to treat to avoid one cardiovascular event was 25.&lt;/p&gt;
&lt;p&gt;Those results, according to Melvyn Rubenfire, MD, of the University of Michigan, were a &quot;home run for JUPITER,&quot; but it is not clear whether the results would be the same with another statin.&lt;/p&gt;
&lt;p&gt;And there were some risks associated with rosuvastatin, including 13 deaths due to gastrointestinal disorders in the rosuvastatin arm, and 18 patients reported experiencing a &quot;confused state&quot; while taking the drug.&lt;/p&gt;
&lt;p&gt;The most troubling adverse event, however, was an uptick in investigator-reported, new onset diabetes mellitus in the treatment arm, 2.8% versus 2.5%, for a hazard ratio of 1.27 (95% CI 1.05 to 1.53, &lt;em&gt;P&lt;/em&gt;=0.015).&lt;/p&gt;
&lt;p&gt;Rosuvastatin in marketed by AstraZeneca, which also sponsored the JUPITER trial.&lt;/p&gt;
    </recommendedItem>
    <recommendedItem id="20100101_19_352"
                     title="ICAO: Future Chronic Disease Risk Goes Beyond BMI (CME/CE)"
                     score="0.01"
                     href="http://www.medpagetoday.com/Endocrinology/Diabetes/tb/18233?impressionId=1265776941503"
                     
      When it comes to predicting chronic disease, body mass index doesn&apos;t tell the whole story, according to a population-based study that found elevated risk with obesity and other metabolic risk factors independently.&lt;br&gt;
&lt;br&gt;Metabolically-healthy obese people tended toward being at least twice as likely to develop multiple metabolic risk factors and diabetes as healthy, normal weight individuals over the subsequent 3.5 years of a study led by Sarah Appleton, a postgraduate student at the University of Adelaide, Australia.&lt;br&gt;
&lt;br&gt;However, normal weight individuals with metabolic risk factors  --  a group the researchers called &quot;metabolically obese&quot;  --  were at greater risk, she told attendees at the International Congress on Abdominal Obesity in Hong Kong, a conference sponsored by the International Chair on Cardiometabolic Risk.&lt;br&gt;
&lt;br&gt;Overall, just 4.1% of the 3,743 adults in the population-based, North West Adelaide Health Study were in the normal body mass index range at baseline but had at least two of the following metabolic risk factors:&lt;ul&gt; &lt;li&gt;Triglyceride levels of 1.7 mmol/L or greater&lt;/li&gt; &lt;li&gt;HDL cholesterol under 1.0mmol/L for men or 1.3 mmol/L for women&lt;/li&gt; &lt;li&gt;Blood pressure of 130/85 mm Hg or higher&lt;/li&gt; &lt;li&gt;A fasting plasma glucose of at least 5.6mmol/L or self-reported diabetes&lt;/li&gt; &lt;li&gt;Treatment for any of these disorders &lt;/li&gt; &lt;/ul&gt;
&lt;p&gt;Although free of cardiovascular disease when they entered the study through a random population sample of the northwest region of Adelaide, after a mean of 3.5 years of follow-up, this group was 2.48 times at risk of incident cardiovascular disease or stroke events (95% CI 1.1 to 5.4).&lt;/p&gt;
&lt;p&gt;Compared with metabolically-healthy, normal weight individuals, those with metabolic risk factors tended to be&lt;strong&gt; &lt;/strong&gt;3.27 times as likely to develop diabetes (&lt;em&gt;P&lt;/em&gt;=0.07).&lt;/p&gt;
&lt;p&gt;Identifying these individuals for prevention efforts may require less emphasis on BMI and increased surveillance of central obesity in primary care, the researchers told the congress.&lt;/p&gt;
&lt;p&gt;&quot;The problem with BMI is it doesn&apos;t tell you where the fat is,&quot; Appleton added in an interview. &quot;Visceral fat is really bad for you.&quot;&lt;/p&gt;
&lt;p&gt;Obese individuals without multiple metabolic risk factors at baseline comprised a larger group (12.1%).&lt;/p&gt;
&lt;p&gt;They were more likely to be middle age, live in a disadvantaged neighborhood, have smoked at some point, and get less exercise than their metabolically similar, but slimmer peers.&lt;/p&gt;
&lt;p&gt;Over the subsequent 3.5 years, they were 2.82 times more likely to develop more than one metabolic risk factor than metabolically-healthy, normal weight individuals (95% CI 2.0 to 4.0).&lt;/p&gt;
&lt;p&gt;The metabolically-normal obese also tended to be 2.36 times more likely to develop diabetes (95% CI 0.8 to 7.1). On the other hand, their risk of cardiovascular disease wasn&apos;t elevated, &quot;which likely related to the younger age of that group,&quot; Appleton told &lt;em&gt;MedPage Today&lt;/em&gt;.&lt;/p&gt;
&lt;p&gt;Notably, abdominal obesity as determined by a waist circumference of 80 cm and over for men or 95 cm and greater for women was 6.1 times more likely among metabolically healthy individuals if their BMI was in the obese versus normal range.&lt;/p&gt;
&lt;p&gt;But those who were in the normal BMI range were 2.2-fold more likely to be overweight or obese according to waist circumference if they had metabolic risk factors, which was statistically significant as well and likely contributed to the health risks they faced over the short-term future, Appleton said.&lt;/p&gt;
&lt;p&gt;Maintenance of metabolic health in the obese population was more likely for younger individuals (OR 2.83 for age 40 or younger, 95% CI 1.1 to 7.6) and those who were at least moderately physically active (OR 2.04, 95% CI 1.01 to 4.1).&lt;/p&gt;
&lt;p&gt;Appleton noted that these findings generally fit with data from the U.S. National Health Assessment Survey and Examination.&lt;/p&gt;
&lt;p&gt;Regardless of whether patients have abdominal obesity, BMI obesity, or other metabolic risk factors, the solution is likely similar  --  improved diet and exercise, she said.&lt;/p&gt;
&lt;div style=&quot;float:left;border-style:solid;border-width:1px;border-color:#8dabbc;font-family:arial;font-size:12px;background-color:#DBE9F2;padding:5px;&quot;&gt;&lt;p&gt;The study was supported by the University of Adelaide and the South Australian Department of Health.&lt;/p&gt;&lt;p&gt;Appleton reported no conflicts of interest.&lt;/p&gt;&lt;/div&gt;&lt;div style=&quot;clear:both;&quot;&gt;&lt;/div&gt;
    </recommendedItem>
    <recommendedItem id="20100101_19_222"
                     title="Benefits of Cutting Down on Salt Quantified (CME/CE)"
                     score="-0.002"
                     href="http://www.medpagetoday.com/Cardiology/Prevention/tb/18075?impressionId=1265776941503"
                     
      &lt;p&gt;Cutting daily salt intake by 3 grams a day  --  about 30% of the current average  --  could prevent 32,000 strokes and 54,000 myocardial infarctions a year, if a computer model developed by researchers at the University of California, San Francisco accurately depicts the clinical impact of salt reduction.&lt;/p&gt;
&lt;p&gt;The results of the analysis, which used a computer simulation of heart disease in U.S. adults ages 35 to 84, also suggest that even a 1 gram per day reduction in salt over the next decade would be a more cost-effective strategy for treating hypertension than use of even the cheapest antihypertensive, wrote Kirsten Bibbins-Domingo, MD, PhD, and colleagues in a paper published online by the &lt;em&gt;New England Journal of Medicine.&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;Lee Goldman, MD, MPH, of Columbia University, who co-authored the paper, told &lt;em&gt;MedPage Today&lt;/em&gt; that their study builds on what has long been known about the adverse health effects of salt on a society that believes it to be the spice of life.&lt;/p&gt;
&lt;p&gt;For example, Goldman said that most people seeking a healthy choice will check food labels and restaurant menus for calorie counts and trans fats, but will not pay attention to salt.&lt;/p&gt;
&lt;p&gt;This is not the first time a call for salt reduction has been issued. As recently as last November, a meta-analysis published in &lt;em&gt;BMJ &lt;/em&gt;suggested that cutting salt intake in half  --  a reduction of about 5 grams a day or roughly a teaspoonful  --  would lower the stroke rate by 23% and reduce overall cardiovascular disease by as much as 17%.&lt;/p&gt;
&lt;p&gt;Americans, like those in many Western countries, take in an average of about 10 g of salt a day; whereas the World Health Organization recommends only 5 g per day, and the U.S. Department of Agriculture recommends daily intake be limited to 5.8 g.&lt;/p&gt;
&lt;p&gt;Bibbins-Domingo and colleagues reported that a 3 gram per day reduction in dietary salt would &quot;save 194,00 to 392,00 quality-adjusted life-years and $10 billion to $24 billion in healthcare costs annually.&quot;&lt;/p&gt;
&lt;p&gt;In an editorial that accompanied the study, Lawrence J. Appel, MD, MPH, and Cheryl A.M. Anderson, PhD, MPH, of Johns Hopkins University, wrote that &quot;the evidence supporting the call to reduce salt intake as a means of preventing cardiovascular disease is compelling.&quot;&lt;/p&gt;
&lt;p&gt;They concluded with this admonition: &quot;As we deliberate healthcare reform, let us not neglect this inexpensive, yet highly effective public health intervention for the prevention of disease.&quot;&lt;/p&gt;
&lt;p&gt;It should be noted that Appel was also first author on a position paper from the American Society of Hypertension that also called for salt reduction as public policy.&lt;/p&gt;
&lt;p&gt;Franz H. Messerli, MD, director of the hypertension program at St. Luke&apos;s-Roosevelt Hospital and a colleague of Goldman&apos;s, said the computer model used in the study was impressive but probably underestimates the benefit of reducing dietary salt &quot;because salt reduction has been shown to have a direct (blood pressure independent) effect on the heart, the brain, the kidneys, and also reduces stomach cancer and osteoporosis  --  factors that were not considered in this analysis.&quot;&lt;/p&gt;
&lt;p&gt;But Messerli found it difficult to lead the victory parade, noting &quot;this is a modeling study and statements such as &apos;A modest reduction of 1 gm per day would be more cost-effective than using medication to lower blood pressure in all persons with hypertension&apos; are to be taken with a good grain of salt.&quot;&lt;/p&gt;
&lt;p&gt;Messerli&apos;s measured response was not echoed by his colleagues in the hypertension world.&lt;/p&gt;
&lt;p&gt;For example, Henry Black, MD, president of the American Society of Hypertension, and director of hypertension research at the New York University School of Medicine said that, although the paper extended the findings of many other studies, it is &quot;more comprehensive and is especially useful by comparing the benefits of [sodium] and [salt] reduction to those of other widely accepted public health approaches that the public and governmental bodies have embraced, including drug treatment.&quot;&lt;/p&gt;
&lt;p&gt;Clyde Yancy, MD, president of the American Heart Association, said that while the study was a computer modeling analysis that may be as good as it gets because &quot;it would be impossible to do a randomized trial in large numbers of high versus low sodium consumption, and the use of modeling with reasonable assumptions represents a solid if not ideal alternative.&quot;&lt;/p&gt;
&lt;p&gt;Moreover, Yancy argued that &quot;the costs and effort involved in setting and/or changing policy&quot; require strong imperatives, and he thought the data reported today &quot;provide that imperative.&quot;&lt;/p&gt;
&lt;p&gt;Three grams of salt comes to about a teaspoonful, but Goldman said it was foolish to think of sodium reduction in terms of such measurements because so much sodium comes from processed foods and from restaurant food. Achieving the needed reduction requires a concerted national effort.&lt;/p&gt;
&lt;p&gt;Bibbins-Domingo noted that their study was limited &quot;by any uncertainty concerning the data entered into the model.&quot;&lt;/p&gt;
&lt;p&gt;Also they noted that they did not &quot;account fully for the possible effects of salt reduction that are unrelated to control of blood pressure  --  for example, potential improvements in outcomes for the increasing numbers of patients with heart failure or prevention of other serious conditions, such as end-stage renal disease.&quot;&lt;/p&gt;
&lt;div style=&quot;float:left;border-style:solid;border-width:1px;border-color:#8dabbc;font-family:arial;font-size:12px;background-color:#DBE9F2;padding:5px;&quot;&gt;&lt;p&gt;The study was supported in part by a grant from the American Heart Association Western States Affiliate and a grant from the University of California, San Francisco Clinical and Translational Sciences Institute.&lt;/p&gt;&lt;p&gt;The authors said they had &quot;no potential conflicts of interest relevant to this article.&quot;&lt;/p&gt;&lt;/div&gt;&lt;div style=&quot;clear:both;&quot;&gt;&lt;/div&gt;&lt;p&gt;&lt;em&gt;This article was developed in collaboration with ABC News. &lt;/em&gt;&lt;img src=&quot;http://www.medpagetoday.com/upload/2009/10/1/14357_1.jpg&quot; mce_src=&quot;http://www.medpagetoday.com/upload/2009/10/1/14357_1.jpg&quot; alt=&quot;&quot;&gt;&lt;/p&gt;
    </recommendedItem>
    <recommendedItem id="20100101_19_169"
                     title="Hospitals Post Gains in Evidence-Based Care"
                     score="-0.003"
                     href="http://www.medpagetoday.com/HospitalBasedMedicine/Hospitalists/tb/17989?impressionId=1265776941503"
                     
      &lt;p&gt;WASHINGTON  --  The latest report from the nation&apos;s official hospital oversight agency, the Joint Commission, found more good than bad  --  overall, hospitals are following evidence-based standards for treatment of myocardial infarction, heart failure, and pneumonia.&lt;/p&gt;
&lt;p&gt;The annual report, &quot;Improving America&apos;s Hospitals: The Joint Commission&apos;s Annual Report on Quality and Safety,&quot; found that hospitals provided evidence-based heart attack treatments  --  including giving patients aspirin when they admitted  --  nearly 97% of the time in 2008, up 10% from the rate in 2002.&lt;/p&gt;
&lt;p&gt;Adherence was even better for treating heart failure. Back in 2002, hospitals treating heart failure patients were only following about 60% of evidence-based recommendations, but in 2008 hospitals were providing evidence-based treatment, including offering smoking cessation counseling and testing left ventricular systolic function, about 92% of the time.&lt;/p&gt;
&lt;p&gt;But mixed in with the glowing words there was a handful of cautions about areas where hospitals still fall short of the mark.&lt;/p&gt;
&lt;p&gt;Hospitals are still often doing too little, too late when it comes to the use of fibrinolytic therapy for MI  --  door-to-needle time only makes the 30-minute threshold about half of the time. A single but important pneumonia measure, initiation of antibiotics within 24 hours of admittance, was also disappointing, with just 60% of hospitals adhering to that measure.&lt;/p&gt;
&lt;p&gt;The Joint Commission&apos;s report tracks hospital use of 31 evidence-based measures.&lt;/p&gt;
&lt;p&gt;On the plus side, hospitals did improve overall adherence to care measures for pneumonia patients, following evidence-based treatment recommendations 93% of the time in 2008, versus 73% in 2002.&lt;/p&gt;
&lt;p&gt;Current guidelines recommend that smokers who are admitted for treatment of acute coronary syndromes, heart failure, or pneumonia should receive smoking cessation counseling, a recommendation that had often been ignored.&lt;/p&gt;
&lt;p&gt;In 2002 hospitals reported providing smoking cessation counseling to about 67% of heart attack patients, 42% of heart failure patients, and 37% of pneumonia patients  --  in 2008 the counseling rate for each of those three admitting diagnoses had climbed to 96% to 99%.&lt;/p&gt;
&lt;p&gt;In the report Mark R. Chassin, MD, Joint Commission president, wrote that improved adherence to evidence-based guidelines should not only improve outcomes, but also save money by reducing both complications and readmissions.&lt;/p&gt;
&lt;p&gt;The report also found that hospitals adhered to quality measures relating to inpatient treatment of childhood asthma  --  which includes giving relievers and systematic corticosteroids for asthmatic kids  --  in nearly 100% of eligible cases. &lt;ul&gt; &lt;/ul&gt;&lt;/p&gt;

    </recommendedItem>
    <recommendedItem id="20090101_19_1997"
                     title="Inhospital Push for Smoking Cessation Boosts Heart Patient Quit Rates"
                     score="-0.005"
                     href="http://www.medpagetoday.com/PrimaryCare/Smoking/tb/14814?impressionId=1265776941503"
                     
      SAN FRANCISCO, June 22 -- Heavy emphasis on smoking cessation while patients are in the hospital recovering from coronary artery bypass surgery or acute MI doubles long-term quit rates, researchers found. 
              &lt;p&gt;
              &lt;p&gt;Catching coronary artery disease patients in this teachable moment &quot;could have a major impact on health and healthcare costs,&quot; said Patricia M. Smith, PhD, of Northern Ontario School of Medicine in Thunder Bay, Ontario, and Ellen Burgess, MD, of the University of Calgary, Alberta. 
              &lt;p&gt;
              &lt;p&gt;Their randomized intervention trial confirmed 12-month tobacco abstinence rates of 54% with intensive inhospital intervention compared with 35% for minimal smoking cessation support (odds ratio 2.0, 95% confidence interval 1.3 to 3.6). 
              &lt;p&gt;
              &lt;p&gt;Self-reported 12-month abstinence rates were likewise doubled with intensive support (62% versus 46%, OR 2.0, 95% CI 1.2 to 3.1), they reported in the June 23 issue of &lt;em&gt;CMAJ&lt;/em&gt;, formerly the &lt;em&gt;Canadian Medical Association Journal&lt;/em&gt;. 
              &lt;p&gt;
              &lt;p&gt;Smoking cessation is one of the most effective, but underutilized, secondary prevention measures, they said. 
              &lt;p&gt;
              &lt;p&gt;&quot;Fifteen years ago, routine smoking-cessation interventions for cardiac patients in hospital were deemed an &apos;idea whose time has come,&apos; but the interventions have not been widely adopted,&quot; Drs. Smith and Burgess wrote. 
              &lt;p&gt;
              &lt;p&gt;Addressing tobacco use should be a cornerstone of secondary prevention efforts, agreed Nancy A. Rigotti, MD, of Massachusetts General Hospital and Harvard, in an accompanying editorial. 
              &lt;p&gt;
              &lt;p&gt;Compared with statins, aspirin, beta-blockers and ACE inhibitors, prior studies in coronary artery disease patients have shown that quitting smoking cuts mortality risk 36%, recurrent nonfatal MI risk 32%, repeat CABG risk 300%, and risk of restenosis after angioplasty from 55% to 38%. 
              &lt;p&gt;
              &lt;p&gt;The reason these kinds of interventions haven&apos;t become usual care may be, in part, that bridging in- and outpatient care for follow-up counseling appears to be critical, Dr. Rigotti noted. 
              &lt;p&gt;
              &lt;p&gt;&quot;Hospitals do not see care after discharge as their responsibility and are not eager to bear the cost,&quot; she wrote. 
              &lt;p&gt;
              &lt;p&gt;Following successful trials of smoking cessation programs in American hospitals, Drs. Smith and Burgess conducted a similar trial in four cardiac units of a large, urban, Canadian hospital. 
              &lt;p&gt;
              &lt;p&gt;In it, 276 sequential patients admitted because of acute MI or for CABG were randomized to an intensive smoking cessation intervention -- 45 minutes to an hour of bedside education and counseling during their hospital stay followed by seven postdischarge nurse-initiated telephone counseling sessions -- or minimal intervention with advice from physicians and nurses and two pamphlets. 
              &lt;p&gt;
              &lt;p&gt;Nicotine replacement pharmacotherapy was suggested as an aid to cessation and was available during the patient&apos;s hospital stay if the patient requested it and a physician ordered it, which 34% in both groups did. 
              &lt;p&gt;
              &lt;p&gt;However, patients in both intervention groups who used pharmacotherapy were significantly less likely to be tobacco-free at 12 months (39% versus 68%, OR 0.3, 95% CI 0.2 to 0.5). 
              &lt;p&gt;
              &lt;p&gt;The effect did not appear to be significantly different between types of intervention (&lt;em&gt;P&lt;/em&gt;=0.26), although Dr. Rigotti cited the low number of patients as a possible reason for the lack of significance. 
              &lt;p&gt;
              &lt;p&gt;She said that this paradoxical finding might reflect confounding because &quot;smokers who are less likely to succeed in quitting because of stronger nicotine dependence are the same smokers who choose to use cessation medication.&quot; 
              &lt;p&gt;
              &lt;p&gt;Factors that did significantly encourage smoking abstinence at 12 months were: 
              &lt;ul&gt;
                &lt;li&gt;Intensive inhospital smoking cessation intervention rather than minimal inhospital support (OR 2.12, 95% CI 1.2 to 3.7)
                &lt;li&gt;Not having a prior history of acute MI before the index admission (OR 2.94, 95% CI 1.3 to 6.5)
                &lt;li&gt;Higher education (OR 2.34 for postsecondary versus high school education or less, 95% CI 1.3 to 4.1)
                &lt;li&gt;Having at least some restrictions on smoking in the home (OR 1.96, 95% CI 1.1 to 3.5)
              &lt;/ul&gt; 
              &lt;p&gt;The researchers noted that almost half of smokers approached for the study did not want to quit smoking or refused to participate. 
              &lt;p&gt;
              &lt;p&gt;&quot;Having a full-time nurse to systematically provide the intensive intervention could help to stress to patients the risk of disease and the importance of quitting, as well as encourage patients to at least try to quit or move them closer to contemplating quitting,&quot; they said. 
              &lt;p&gt;
              &lt;p&gt;If resources allow, nurses could attempt to deliver the minimal advice-and-pamphlet intervention to encourage smoking cessation as well, they said. 
              &lt;p&gt;
              &lt;p&gt;They noted that the findings might not generalize to patients with substance abuse or psychiatric comorbidities, who were excluded in the study and may need services beyond what the counselors were able to provide.   
              &lt;p&gt;
              &lt;p&gt;&lt;table cellspacing=&quot;0&quot; hspace=&quot;1&quot; style=&quot;border-style:solid; border-width:1px; border-color:#8dabbc; font-family:arial; font-size:12px; background-color:#DBE9F2; padding:5px 5px 5px 5px;&quot;&gt;
&lt;tr&gt;&lt;td&gt;The study was funded by the Calgary Health Region Health Promotion Fund, Aventis Canada, Merck Frosst Canada, and Pfizer Canada. 
              &lt;p&gt;Dr. Smith reported receiving travel assistance from Pfizer, which manufactures a nicotine-replacement product, to attend a conference on treatment of tobacco dependence. 
              &lt;p&gt;Dr. Rigotti reported receiving payment and travel expenses from Pfizer and Free and Clear, which provides telephone-based counseling for smoking cessation. She also reported research grants from Pfizer, sanofi aventis, and Nabi Biopharmaceuticals for studies of approved and investigational smoking cessation products.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
        
    </recommendedItem>
</recommendedContent>
